Want to see AU:ATX full AI Analyst Report?
Top Page
Amplia Therapeutics
(Sydney:ATX)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.15
â–²(3.57% Upside)
Action:Reiterated
Date:05/30/26
The score is driven primarily by weak financial performance—zero revenue in the latest year, persistent losses, and worsening cash burn—partly offset by a comparatively strong equity-backed balance sheet. Technicals are also soft with the price below key moving averages and negative MACD, while valuation is difficult to support due to negative earnings and no dividend yield data.
Positive Factors
Balance sheet equity cushion
A large equity base relative to assets provides a meaningful capital cushion, lowering near-term insolvency risk. This durability supports ongoing clinical programs and gives management financing flexibility and negotiating leverage with partners over the next several months without forcing immediate distress financing.
Negative Factors
Zero revenue in latest year
No reported revenue in 2026 means the business lacks product commercialization and recurring cash inflows. This structural absence of revenue forces reliance on capital markets or partners for runway, reduces optionality, and increases execution risk for clinical programs over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet equity cushion
A large equity base relative to assets provides a meaningful capital cushion, lowering near-term insolvency risk. This durability supports ongoing clinical programs and gives management financing flexibility and negotiating leverage with partners over the next several months without forcing immediate distress financing.
Read all positive factors
Amplia Therapeutics (ATX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$74.43M
Dividend YieldN/A
Average Volume (3M)525.22K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue GrowthN/A
EPS Growth21.23%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding513,312,000
10 Day Avg. Volume444,673
30 Day Avg. Volume525,217
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-12.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.42Price Target Upside200.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Amplia Therapeutics Business Overview & Revenue Model
Company Description
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor o...
How the Company Makes Money
null...
Amplia Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 3.78M | 4.45M | 1.19M | 1.98M |
| Gross Profit | -92.14K | 3.57M | 4.01M | 1.12M | 1.98M |
| EBITDA | -13.09M | -6.78M | -4.48M | -7.26M | -3.64M |
| Net Income | -7.71M | -6.57M | -4.50M | -6.24M | -3.64M |
Balance Sheet | |||||
| Total Assets | 41.44M | 22.94M | 14.85M | 18.68M | 24.48M |
| Cash, Cash Equivalents and Short-Term Investments | 27.85M | 10.86M | 3.39M | 9.26M | 14.61M |
| Total Debt | 341.11K | 13.89K | 1.59M | 2.27M | 2.10M |
| Total Liabilities | 1.97M | 1.91M | 3.43M | 2.85M | 2.64M |
| Stockholders Equity | 39.47M | 21.02M | 11.42M | 15.84M | 21.85M |
Cash Flow | |||||
| Free Cash Flow | -8.77M | -6.89M | -5.13M | -5.31M | -4.42M |
| Operating Cash Flow | -8.73M | -6.89M | -5.13M | -5.29M | -4.40M |
| Investing Cash Flow | -96.22K | -2.07K | -2.23K | -58.42K | -26.64K |
| Financing Cash Flow | 25.94M | 14.32M | -772.98K | -84.22K | 17.19M |
Amplia Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$2.99B | 97.71 | 9.20% | ― | -69.69% | -78.38% | |
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$116.62M | -6.65 | -30.19% | ― | ― | 62.66% | |
45 Neutral | AU$58.77M | -15.65 | -68.12% | ― | ― | 57.89% | |
43 Neutral | AU$74.43M | -8.68 | -18.71% | ― | ― | 21.23% | |
43 Neutral | AU$107.85M | -2.02 | -265.55% | ― | -26.58% | -100.90% |
* Healthcare Sector Average
AU:ATX
Amplia Therapeutics
0.15
-0.06
-27.50%
AU:ENP
Tryptamine Therapeutics
0.04
<0.01
9.09%
AU:NEU
Neuren Pharmaceuticals Limited
23.45
6.39
37.46%
AU:PAR
Paradigm Biopharmaceuticals
0.18
-0.14
-42.86%
AU:ATH
Alterity Therapeutics
0.55
-0.10
-16.15%
AU:ZLD
Zelira Therapeutics
0.50
0.09
21.95%
Amplia Therapeutics Corporate Events
Amplia Showcases Lead FAK Inhibitor as Pancreatic Cancer Data Strengthen Oncology Push
Aug 6, 2026
Amplia Therapeutics has released a presentation for the Bioshares Biotech Summit in Queenstown, where Managing Director Dr Chris Burns will outline the company’s strategy of targeting pancreatic cancer and other fibrotic indications with its...
Amplia bolsters narmafotinib case with comprehensive pancreatic cancer data
Jul 30, 2026
Amplia Therapeutics has highlighted new preclinical research on its lead FAK inhibitor narmafotinib in pancreatic cancer, now available on the bioRxiv server. The studies, led by Professor Paul Timpson at the Garvan Institute, explore how narmafot...
Amplia advances FAK inhibitor program with new trials, patent gains and board refresh
Jul 28, 2026
Amplia reported mature data from its ACCENT trial in metastatic pancreatic cancer showing that its FAK inhibitor narmafotinib, added to standard chemotherapy, delivered favourable safety and improved efficacy across key measures, including higher ...
Amplia Therapeutics Issues New Employee Incentive Options
Jul 15, 2026
Amplia Therapeutics has notified the ASX of the issue of 987,592 unquoted options under its employee incentive scheme. The options, exercisable at $0.19 and expiring on July 15, 2028, are not intended to be quoted on the exchange.The new options g...
Amplia Therapeutics Issues New Employee Incentive Options
Jul 15, 2026
Amplia Therapeutics has notified the market of the issue of 1,272,099 unquoted Zero Exercise Price Options under its employee incentive scheme. The options, which are not intended to be quoted on the ASX, were issued on July 15, 2026, and reflect ...
Amplia Therapeutics appoints Brett Carter as director amid progress in pancreatic cancer trials
Jul 6, 2026
Amplia Therapeutics Limited has filed an Initial Director’s Interest Notice announcing the appointment of Brett Anthony Carter as a director of the company, noting that he currently holds no relevant interests in Amplia’s securities. T...
Amplia strengthens board with industry deal-maker Brett Carter
Jul 5, 2026
Amplia Therapeutics has appointed biopharmaceutical executive Brett Carter as a non-executive director, strengthening its board as lead drug narmafotinib moves into later-stage development. Carter brings more than 25 years of global oncology, corp...
Amplia Therapeutics Sets August AGM Amid Progress in FAK Cancer Trials
Jun 30, 2026
Amplia Therapeutics has scheduled its Annual General Meeting for Friday 28 August 2026, covering the financial year ended 31 March 2026, with venue and detailed arrangements to be confirmed. The company has also opened nominations for the election...
Amplia Therapeutics reshapes board leadership as clinical momentum builds
Jun 29, 2026
Amplia Therapeutics has announced a planned change in board leadership as part of its renewal and succession strategy, with long-serving chairman Dr Warwick Tong stepping down from the chair role while remaining on the board as a non-executive dir...
Amplia lodges updated ASX corporate governance statement for 2026
May 29, 2026
Amplia Therapeutics has lodged its updated corporate governance statement for the year ended 31 March 2026, confirming that the document is current as of 27 May 2026 and is available on its website. The filing, accompanied by a completed Appendix ...
Amplia Therapeutics details ASX-aligned corporate governance framework
May 29, 2026
Amplia Therapeutics has formalised its governance framework in line with the ASX Corporate Governance Council’s latest principles, detailing a clear Board Charter that defines the respective roles of directors and management. The board retai...
Amplia Highlights Cancer and Fibrosis Focus in 2025-26 Report
May 29, 2026
Amplia Therapeutics has released its 2025-2026 annual report, underscoring its commitment to innovating therapies for cancer and fibrotic diseases. The report positions the company as a purpose-driven biotech player, highlighting its broader focus...
Amplia Issues New Shares Under Executive Equity Plan, Affirms Regulatory Compliance
May 12, 2026
Amplia Therapeutics has issued 240,385 fully paid ordinary shares following the exercise of Zero Exercise Price Options granted to its Chief Medical Officer under the company’s Equity Incentive Plan. The new shares rank equally with existing...
Amplia Therapeutics Adds 240,385 New Shares to ASX Listing
May 12, 2026
Amplia Therapeutics Limited has applied for quotation of 240,385 new ordinary fully paid shares on the Australian Securities Exchange. The new securities, issued on May 12, 2026, arise from the exercise or conversion of existing options or other c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.